Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3301
iShares US Infrastructure ETF
IFRA
$4.63B
| $203K | ﹤0.01% |
+5,200
| New | +$194K |
|
3302
AquaBounty Technologies
AQB
$7.31M
| $202K | ﹤0.01% |
28,470
-5,410
| -16% | -$52.3K |
|
|
CBIO
3303
Crescent Biopharma
CBIO
$618M
| $202K | ﹤0.01% |
1,161
-270
| -19% | -$45.3K |
|
3304
HF Foods Group
HFFG
$96.5M
| $201K | ﹤0.01% |
42,900
+5,800
| +16% | +$22.7K |
|
3305
Protara Therapeutics
TARA
$233M
| $200K | ﹤0.01% |
83,600
+24,694
| +42% | +$73.4K |
|
3306
P3 Health Partners
PIII
$35.8M
| $199K | ﹤0.01% |
+1,331
| New | +$184K |
|
3307
Beam Global
BEEM
$25.5M
| $198K | ﹤0.01% |
+19,100
| New | +$209K |
|
3308
Mayville Engineering Co
MEC
$601M
| $198K | ﹤0.01% |
+15,900
| New | +$201K |
|
3309
electroCore
ECOR
$85.3M
| $197K | ﹤0.01% |
40,305
+11,061
| +38% | +$60.5K |
|
|
OGG
3310
Osisko Gold Group Inc.
OGG
$826M
| $196K | ﹤0.01% |
42,700
+21,100
| +98% | +$103K |
|
|
ICD
3311
DELISTED
Independence Contract Drilling, Inc.
ICD
| $196K | ﹤0.01% |
71,844
-60,924
| -46% | -$178K |
|
3312
a.k.a. Brands
AKA
$118M
| $191K | ﹤0.01% |
37,000
+28,983
| +362% | +$141K |
|
3313
American Shared Hospital Services
AMS
$9.94M
| $191K | ﹤0.01% |
74,795
+29,595
| +65% | +$81.4K |
|
3314
Companhia Siderúrgica Nacional
SID
$1.2B
| $191K | ﹤0.01% |
73,700
-362,813
| -83% | -$1,000K |
|
|
WKME
3315
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| $191K | ﹤0.01% |
19,900
+2,700
| +16% | +$26.2K |
|
3316
Anixa Biosciences
ANIX
$111M
| $190K | ﹤0.01% |
59,300
+37,998
| +178% | +$146K |
|
|
VIRX
3317
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $190K | ﹤0.01% |
134,799
+9,500
| +8% | +$13.6K |
|
|
KORE
3318
DELISTED
KORE Group Holdings
KORE
| $189K | ﹤0.01% |
31,060
+22,340
| +256% | +$148K |
|
|
TMQ
3319
Trilogy Metals
TMQ
$648M
| $188K | ﹤0.01% |
317,300
+198,800
| +168% | +$112K |
|
3320
Palladyne AI
PDYN
$310M
| $188K | ﹤0.01% |
97,240
-1,647
| -2% | -$3.93K |
|
3321
GDS Holdings
GDS
$6.85B
| $187K | ﹤0.01% |
17,000
+1,000
| +6% | +$13.3K |
|
|
GRCL
3322
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $187K | ﹤0.01% |
49,100
+200
| +0.4% | +$560 |
|
3323
Richmond Mutual Bancorp
RMBI
$257M
| $184K | ﹤0.01% |
16,642
+500
| +3% | +$5.19K |
|
3324
HeartCore Enterprises
HTCR
$3.52M
| $182K | ﹤0.01% |
6,378
+5,103
| +400% | +$130K |
|
3325
INmune Bio
INMB
$58M
| $182K | ﹤0.01% |
20,000
-14,800
| -43% | -$119K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.